Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) said on Sunday that it has updated the findings from two studies that provide further highlights the importance of Veklury (remdesivir) for the treatment of hospitalized and non-hospitalized patients with COVID-19.
The company revealed the first study retrospective observational analysis of the real-world treatment data from the Premier Healthcare Database consisted of 853,219 patients hospitalized with COVID-19 across the US.
An oral presentation of this real-world data analysis will be given on 25 April at 11:00 Western European Summer Time in Hall P at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022), added the company.
A separate study, which is a new post-hoc analysis of data from the Phase 3 PINETREE study, demonstrated that use of Veklury within five days of symptom onset or between five to seven days of symptom onset reduced hospitalizations in patients at high risk for severe COVID-19 disease. This post-hoc analysis was presented as a poster at ECCMID, disclosed the company.
Additionally, the company presented two additional studies from its COVID-19 clinical and real-world evidence programmes at the conference. Veklury was generally well tolerated, with a high proportion of participants showing clinical improvement and recovery.
Veklury is a nucleotide analog that directly inhibits viral replication inside of the cell by targeting the SARS-CoV-2 viral RNA polymerase.Veklury (remdesivir 100 mg for injection) is indicated for the treatment of COVID-19 in adults and pediatric patients (12 years of age and older and weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, concluded the company.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer